Prediction: This Nuclear Stock Outperforms Oklo and NuScale Through 2030 (Hint: It Already Has Revenue)
2026-10-02 16:30
•Jeff Siegel •The Motley Fool
•• ••• Axe Cap view
BWXT Leads Nuclear Innovation, But Is SA Missing Out?
BWXT’s established revenue and diversified operations position it to outpace emerging modular nuclear peers—though South Africa’s market impact remains limited.
BWX Technologies (BWXT) stands out among nuclear players with $3.2 billion in current revenue and a raised 2026 guideline reflecting strong 19% growth. Unlike Oklo and NuScale, which are still betting on proving their reactor designs, BWXT's steady income comes from established U.S. Navy contracts, nuclear fuel production, and medical isotopes. For South Africa investors, nuclear innovation feels distant. The JSE doesn’t list any nuclear pure-plays, and while Eskom's Kusile plant still struggles, government nuclear ambitions remain on hold. The USD/ZAR will likely respond to global energy shifts, but direct stock plays like BWXT are inaccessible locally. This means exposure may come through global funds or currency plays. If BWXT’s growth slows or U.S. defense budgets shrink, its premium position may erode. Investors new to energy tech should watch how modular reactors develop but focus on sectors with better local access like energy or mining. this is just our opinion and not financial advice
Avoid direct nuclear stocks due to lack of local listings, but watch for further USD/ZAR strength if energy inflation eases on nuclear progress. Keep exposure to resource-linked counters that benefit from broader energy themes.
- BWXT
- USD/ZAR
- Delay or failure in US modular nuclear adoption
- South African government delaying nuclear projects further
5/10
BWX Technologies is positioned to outperform nuclear peers Oklo and NuScale through 2030 due to its established $3.2 billion revenue base and decades of nuclear manufacturing experience. While Oklo and NuScale are still commercializing reactor technologies, BWXT generates revenue from U.S. Navy contracts, TRISO fuel production, medical isotopes, and is developing advanced reactors and microreactors. The company raised its 2026 revenue guidance to $3.8 billion with 19% growth expected.
Our take is based on reporting first published by The Motley Fool.